These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25936304)

  • 21. Increasing plasma lysophosphatidylcholine levels in patients with regular dextran sulfate lipoprotein apheresis.
    Graessler J; Schuhmann K; Shevchenko A; Kopprasch S; Ban R; Bergmann S; Bornstein SR; Hohenstein B; Julius U
    Atheroscler Suppl; 2015 May; 18():170-5. PubMed ID: 25936322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies.
    Bambauer R; Schiel R; Latza R
    Ther Apher; 2000 Jun; 4(3):213-7. PubMed ID: 10910023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homocysteine in lipoprotein apheresis patients--retrospective data analysis in apheresis center of a university hospital.
    Tselmin S; Rodionov RN; Müller G; Bornstein S; Julius U
    Atheroscler Suppl; 2013 Jan; 14(1):123-8. PubMed ID: 23357153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
    Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein apheresis standard for apheresis competence centers--an updated synthesis and amendment to pre-existing standards.
    Heigl F; Hettich R; Eder B; Arendt R
    Atheroscler Suppl; 2013 Jan; 14(1):57-65. PubMed ID: 23357142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein apheresis: state of the art and novelties.
    Stefanutti C; Julius U
    Atheroscler Suppl; 2013 Jan; 14(1):19-27. PubMed ID: 23357136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of different lipid apheresis methods on plasma polyunsaturated fatty acids.
    Schmöcker C; Kassner U; Ostermann AI; Kiesler S; Steinhagen-Thiessen E; Schebb NH; Weylandt KH
    Atheroscler Suppl; 2017 Nov; 30():193-199. PubMed ID: 29096838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
    Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?
    Heigl F; Pflederer T; Klingel R; Hettich R; Lotz N; Reeg H; Schettler VJJ; Roeseler E; Grützmacher P; Hohenstein B; Julius U
    Atheroscler Suppl; 2019 Dec; 40():23-29. PubMed ID: 31818446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters--A comparison of two different apheresis techniques.
    Kopprasch S; Bornstein SR; Bergmann S; Graessler J; Julius U
    Atheroscler Suppl; 2015 May; 18():80-4. PubMed ID: 25936309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
    Schatz U; Tselmin S; Müller G; Julius U; Hohenstein B; Fischer S; Bornstein SR
    Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels.
    Lamounier-Zepter V; Look C; Ehrhart-Bornstein M; Bornstein SR; Fischer S; Julius U
    Atheroscler Suppl; 2013 Jan; 14(1):129-34. PubMed ID: 23357154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
    Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Leebmann J; Lehmacher W; Kamstrup PR; Nordestgaard BG; Maerz W; Noureen A; Schmidt K; Kronenberg F; Heibges A; Klingel R;
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a).
    Poller WC; Dreger H; Morgera S; Berger A; Flessenkämper I; Enke-Melzer K
    Atheroscler Suppl; 2015 May; 18():187-93. PubMed ID: 25936325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial.
    Khan TZ; Pottle A; Pennell DJ; Barbir MS
    Atheroscler Suppl; 2015 May; 18():103-8. PubMed ID: 25936312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels.
    Schettler VJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F;
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):14-20. PubMed ID: 25652812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipoprotein apheresis in Austria - Reduction of cardiovascular events by regular lipoprotein apheresis treatment.
    Berent T; Derfler K; Berent R; Sinzinger H
    Atheroscler Suppl; 2019 Dec; 40():8-11. PubMed ID: 31818453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.
    Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):8-13. PubMed ID: 25672934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
    Wagner S; Janzen RW; Mohs C; Pohlmann S; Klingel R; Grützmacher PW
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2377-82. PubMed ID: 18988129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life in patients treated with lipoprotein apheresis.
    Rosada A; Kassner U; Banisch D; Bender A; Steinhagen-Thiessen E; Vogt A
    J Clin Lipidol; 2016; 10(2):323-9.e6. PubMed ID: 27055963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.